Form 4: Kura Oncology Director Faheem Hasnain Executes Stock Transactions Under 10b5-1 Plan

Director Faheem Hasnain of Kura Oncology, Inc. reports stock transactions, including acquisitions and disposals, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On March 21, 2025, Faheem Hasnain, a director of Kura Oncology, Inc., engaged in transactions involving the company's common stock.
• These transactions included the acquisition of 22,682 shares at a price of $6.32 and the disposal of 22,682 shares at a weighted average price of $8.00.
• Following these transactions, Hasnain beneficially owns 23,983 shares of Kura Oncology common stock.
• The reported transactions were executed according to a pre-arranged Rule 10b5-1 trading plan adopted on June 20, 2024.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment.

Industry Context

This filing is a routine disclosure of stock transactions by a company insider. It's common for executives and directors to use 10b5-1 plans to avoid accusations of insider trading.

Stakeholder Impact

• The transactions may have a minor impact on shareholders, depending on the overall market perception of insider trading activity.

Key Dates

Keywords

Kura Oncology, Director, Faheem Hasnain, Stock Transactions, Form 4, Rule 10b5-1, Beneficial Ownership